Enfusion logo

EnfusionNYSE: ENFN

Profile

Sector:

Technology

Country:

United States

IPO:

21 October 2021

Next earnings report:

12 March 2025

Last dividends:

N/A

Next dividends:

N/A
$904.08 M
-35%vs. 3y high
51%vs. sector
239.50
-26%vs. 3y high
94%vs. sector
-48%vs. 3y high
91%vs. sector
-66%vs. 3y high
67%vs. sector

Price

pre-market | 41 min ago
$9.58-$0.14(-1.44%)

Dividend

No data over the past 3 years
$51.17 M$54.66 M
$51.17 M$1.42 M

Analysts recommendations

Institutional Ownership

ENFN Latest News

Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: NEUTRAL

Enfusion, Inc. (NYSE:ENFN ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - Chief Executive Officer Bradley Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Parker Lane - Stifel Kevin McVeigh - UBS Elise Kenner - JP Morgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Crispin Love - Piper Sandler Operator Good morning, ladies and gentlemen. Thank you for standing by.

Enfusion, Inc. (ENFN) Q3 Earnings and Revenues Miss Estimates
zacks.com04 November 2024 Sentiment: NEUTRAL

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.

Enfusion, Inc. Is Being Looked Into For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com01 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Enfusion, Inc. For Possible Securities Fraud
accesswire.com29 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
accesswire.com27 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The Schall Law Firm Is Inquiring Into Enfusion, Inc. For Possible Securities Fraud And Stockholders With Losses Should Take Part
accesswire.com27 September 2024 Sentiment: NEGATIVE

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out
accesswire.com26 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Urged To Join The Schall Law Firm's Investigation Into Enfusion, Inc. For Possible Securities Fraud
accesswire.com25 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
accesswire.com23 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The Schall Law Firm Is Investigating Enfusion, Inc. For Possible Securities Fraud And Affected Shareholders Are Urged To Lend A Hand
accesswire.com23 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Enfusion?

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

What sector is Enfusion in?

Enfusion is in the Technology sector

What industry is Enfusion in?

Enfusion is in the Software Application industry

What country is Enfusion from?

Enfusion is headquartered in United States

When did Enfusion go public?

Enfusion initial public offering (IPO) was on 21 October 2021

What is Enfusion website?

https://www.enfusion.com

Is Enfusion in the S&P 500?

No, Enfusion is not included in the S&P 500 index

Is Enfusion in the NASDAQ 100?

No, Enfusion is not included in the NASDAQ 100 index

Is Enfusion in the Dow Jones?

No, Enfusion is not included in the Dow Jones index

When was Enfusion the previous earnings report?

No data

When does Enfusion earnings report?

The next expected earnings date for Enfusion is 12 March 2025